Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pradefovir Extension Study in Chronic Hepatitis B
NCT00230490Phase 2Terminated
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jun 2005
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 2, open-label trial of pradefovir in Chronic Hepatitis B (CHB) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Clinical examinations of laboratory tests and Change in viral load over time. Started Jun 2005; status: terminated.
02
Drugs
pradefovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00230490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230490.